PDC-lung is under clinical development by PDC Line Pharma and currently in Phase II for Non-Small Cell Lung Cancer. According to GlobalData, Phase II drugs for Non-Small Cell Lung Cancer have a 38% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how PDC-lung’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

PDC-lung overview

PDC-lung is under development for the treatment of squamous and non-squamous non-small cell lung cancer. It is administered as a suspension through intravenous and subcutaneous route. The therapeutic candidate is constitutes irradiated human plasmacytoid dendritic cells (PDC) loaded with a synthetic peptide encoded by lung tumor antigens including NY-ESO-1, MAGE-A3, MAGEA4, Multi-MAGE, SURVIVN and MUC1. It is developed based on PDC-line platform.

PDC Line Pharma overview

PDC Line Pharma, is a healthcare company that provides immuno-oncology services that focuses on development of immunotherapies based on a proprietary PDC. The company is headquartered in France.

For a complete picture of PDC-lung’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.